Acumen Pharmaceuticals Inc
ABOS
Company Profile
Business description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Contact
1210-1220 Washington Street
Suite 210
NewtonMA02465
USAT: +1 617 344-4190
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
52
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,833.40 | 4.70 | 0.05% |
| CAC 40 | 7,738.42 | 75.83 | 0.99% |
| DAX 40 | 23,790.11 | 116.82 | 0.49% |
| Dow JONES (US) | 44,484.42 | 10.52 | -0.02% |
| FTSE 100 | 8,774.69 | 10.64 | -0.12% |
| HKSE | 24,035.74 | 185.67 | -0.77% |
| NASDAQ | 20,393.13 | 190.24 | 0.94% |
| Nikkei 225 | 39,705.50 | 56.98 | -0.14% |
| NZX 50 Index | 12,704.48 | 79.81 | -0.62% |
| S&P 500 | 6,227.42 | 29.41 | 0.47% |
| S&P/ASX 200 | 8,596.40 | 1.30 | -0.02% |
| SSE Composite Index | 3,462.83 | 8.04 | 0.23% |